Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT02657889 |
Title | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO) |
Acronym | TOPACIO |
Recruitment | Completed |
Gender | both |
Phase | Phase Ib/II |
Variant Requirements | No |
Sponsors | Tesaro, Inc. |
Indications | |
Therapies | |
Age Groups: | senior | adult |
Covered Countries | USA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
GSK Investigational Site | Birmingham | Alabama | 35249 | United States | Details | |
GSK Investigational Site | Phoenix | Arizona | 85054 | United States | Details | |
GSK Investigational Site | Scottsdale | Arizona | 85258 | United States | Details | |
GSK Investigational Site | Los Angeles | California | 90048 | United States | Details | |
GSK Investigational Site | San Francisco | California | 94115 | United States | Details | |
GSK Investigational Site | Stanford | California | 94305 | United States | Details | |
GSK Investigational Site | Washington | District of Columbia | 20007 | United States | Details | |
GSK Investigational Site | Deerfield Beach | Florida | 33442 | United States | Details | |
GSK Investigational Site | Jacksonville | Florida | 32224 | United States | Details | |
GSK Investigational Site | Miami | Florida | 33136 | United States | Details | |
GSK Investigational Site | Orlando | Florida | 32804 | United States | Details | |
GSK Investigational Site | Chicago | Illinois | 60637 | United States | Details | |
GSK Investigational Site | Covington | Louisiana | 70433 | United States | Details | |
GSK Investigational Site | Boston | Massachusetts | 02111 | United States | Details | |
GSK Investigational Site | Boston | Massachusetts | 02114 | United States | Details | |
GSK Investigational Site | Boston | Massachusetts | 02115 | United States | Details | |
GSK Investigational Site | Burlington | Massachusetts | 01805 | United States | Details | |
GSK Investigational Site | Detroit | Michigan | 48201 | United States | Details | |
GSK Investigational Site | Rochester | Minnesota | 55905 | United States | Details | |
GSK Investigational Site | Morristown | New Jersey | 07962 | United States | Details | |
GSK Investigational Site | New York | New York | 10065 | United States | Details | |
GSK Investigational Site | Chapel Hill | North Carolina | 27514 | United States | Details | |
GSK Investigational Site | Charlotte | North Carolina | 28204 | United States | Details | |
GSK Investigational Site | Cleveland | Ohio | 44106 | United States | Details | |
GSK Investigational Site | Oklahoma City | Oklahoma | 73104 | United States | Details | |
GSK Investigational Site | Germantown | Tennessee | 38138 | United States | Details | |
GSK Investigational Site | Nashville | Tennessee | 37203 | United States | Details | |
GSK Investigational Site | San Antonio | Texas | 78229 | United States | Details | |
GSK Investigational Site | Charlottesville | Virginia | 22903 | United States | Details | |
GSK Investigational Site | Seattle | Washington | 98109 | United States | Details |